NASDAQ:SNCE Science 37 - SNCE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Science 37 Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.44 0.00 (0.00%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.42▼$0.4750-Day Range$0.37▼$0.7552-Week Range$0.32▼$9.97Volume542,330 shsAverage Volume406,050 shsMarket Capitalization$51.09 millionP/E RatioN/ADividend YieldN/APrice Target$3.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Science 37 MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside756.4% Upside$3.75 Price TargetShort InterestHealthy1.39% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.99Based on 4 Articles This WeekInsider TradingAcquiring Shares$4,050 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.90) to ($0.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.68 out of 5 starsMedical Sector86th out of 1,054 stocksCommercial Physical Research Industry2nd out of 17 stocks 3.4 Analyst's Opinion Consensus RatingScience 37 has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.75, Science 37 has a forecasted upside of 756.4% from its current price of $0.44.Amount of Analyst CoverageScience 37 has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.39% of the float of Science 37 has been sold short.Short Interest Ratio / Days to CoverScience 37 has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Science 37 has recently decreased by 24.29%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldScience 37 does not currently pay a dividend.Dividend GrowthScience 37 does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SNCE. Previous Next 3.9 News and Social Media Coverage News SentimentScience 37 has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Science 37 this week, compared to 1 article on an average week.Search Interest1 people have searched for SNCE on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Science 37 to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Science 37 insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,050.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Science 37 is held by insiders.Percentage Held by Institutions50.85% of the stock of Science 37 is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Science 37 are expected to grow in the coming year, from ($0.90) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Science 37 is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Science 37 is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioScience 37 has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Science 37 (NASDAQ:SNCE) StockScience 37 Holdings, Inc. provides technology-based solutions to enable agile clinical trials and decentralized approaches. Its platform enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, and sponsors to power workflows, centralize evidence generation, and harmonize data. Its platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating agile clinical trials; and extensive configuration to support virtually any phase of clinical study and any indication. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.Read More Receive SNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Science 37 and its competitors with MarketBeat's FREE daily newsletter. Email Address SNCE Stock News HeadlinesJanuary 25, 2023 | americanbankingnews.comScience 37 (NASDAQ:SNCE) versus OmniAb (NASDAQ:OABI) Critical ContrastDecember 9, 2022 | finance.yahoo.comScience 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)January 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 30, 2022 | technews.tmcnet.comScience 37 to Present at the 5?? Annual Evercore ISI HealthCONx ConferenceNovember 30, 2022 | finance.yahoo.comScience 37 to Present at the 5ᵗʰ Annual Evercore ISI HealthCONx ConferenceNovember 22, 2022 | finance.yahoo.comScience 37 and BEKHealth Collaborate to Expand Patient Access Via Community ProvidersNovember 17, 2022 | finance.yahoo.comScience 37 and Linical Announce Partnership to Enable Fully Decentralized and Hybrid TrialsNovember 16, 2022 | uk.finance.yahoo.comThings Look Grim For Science 37 Holdings, Inc. (NASDAQ:SNCE) After Today's DowngradeJanuary 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 15, 2022 | finance.yahoo.comScience 37 Named Best in Class for Telehealth Innovation at UCSF Health Hub Digital Health Awards 2022November 15, 2022 | finance.yahoo.comScience 37 Named Best in Class for Telehealth Innovation at UCSF Health Hub Digital Health Awards 2022November 14, 2022 | bizjournals.comRTP firm slashing 90 jobs as headwinds continue for life sciencesNovember 14, 2022 | bizjournals.comScience 37 slashing 90 jobs as headwinds continue for life sciencesNovember 10, 2022 | msn.comScience 37 Holdings, Inc. (SNCE) Reports Q3 Loss, Misses Revenue EstimatesNovember 10, 2022 | finance.yahoo.comScience 37 Reports Third Quarter 2022 Financial ResultsNovember 1, 2022 | finance.yahoo.comScience 37 to Report Third Quarter 2022 Financial Results on November 10, 2022October 12, 2022 | uk.finance.yahoo.comFurther weakness as Science 37 Holdings (NASDAQ:SNCE) drops 28% this week, taking one-year losses to 88%October 5, 2022 | finance.yahoo.comScience 37 appoints Paul von Autenried to its Board of DirectorsSeptember 12, 2022 | finance.yahoo.comScience 37 Names Industry Veteran Michael Shipton as Chief Commercial OfficerSeptember 8, 2022 | apnews.comScience 37 to Present at the Baird 2022 Global Healthcare ConferenceSeptember 8, 2022 | finance.yahoo.comScience 37 to Present at the Baird 2022 Global Healthcare ConferenceSeptember 6, 2022 | msn.comThe Under-the-Radar Stock Simplifying Clinical TrialsAugust 24, 2022 | finance.yahoo.comNew Science Technology Accelerates Patient Recruitment and EnrollmentAugust 18, 2022 | finance.yahoo.comScience 37 and Syapse Partner to Enable Faster Patient Enrollment in Oncology Clinical TrialsAugust 18, 2022 | apnews.comScience 37 and Syapse Partner to Enable Faster Patient Enrollment in Oncology Clinical TrialsAugust 17, 2022 | finance.yahoo.comRTP science firm slashes revenue target amid strategy shiftAugust 16, 2022 | nasdaq.comScience 37 Holdings, Inc. (NASDAQ:SNCE) Just Reported, And Analysts Assigned A US$6.25 Price TargetSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Science 37 and its competitors with MarketBeat's FREE daily newsletter. Email Address SNCE Company Calendar Last Earnings11/10/2022Today1/28/2023Next Earnings (Estimated)3/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNCE CUSIPN/A CIK1819113 Webwww.lifesciacquisition.com Phone984-377-3737FaxN/AEmployees601Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.75 High Stock Price Forecast$7.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+756.4%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,330,000.00 Net Margins-66.46% Pretax Margin-66.45% Return on Equity-72.32% Return on Assets-51.04% Debt Debt-to-Equity RatioN/A Current Ratio6.32 Quick Ratio6.32 Sales & Book Value Annual Sales$59.60 million Price / Sales0.86 Cash FlowN/A Price / Cash FlowN/A Book Value$1.06 per share Price / Book0.41Miscellaneous Outstanding Shares116,660,000Free Float111,531,000Market Cap$51.09 million OptionableNot Optionable Beta0.98 Key ExecutivesMr. David Coman (Age 52)CEO & Director Comp: $787.05kMs. Christine A. Pellizzari J.D. (Age 54)Chief Legal & HR Officer and Sec. Comp: $606.91kMr. Mike Zaranek (Age 51)Chief Financial Officer Troy BryentonChief Technology OfficerMs. Margie Gimbel KoomanVP of Marketing & CommunicationsMr. Drew BustosChief Strategy & Marketing OfficerMr. Jonathan Cotliar M.D. (Age 50)Chief Medical Officer Ms. Darcy Forman (Age 47)Chief Delivery Officer Ms. Elisa CascadeChief Product OfficerMr. Michael Shipton (Age 50)Chief Commercial Officer More ExecutivesKey CompetitorsSunshine BiopharmaNASDAQ:SBFMAIkido PharmaNASDAQ:AIKIiSpecimenNASDAQ:ISPCData Knights AcquisitionNASDAQ:DKDCAInotivNASDAQ:NOTVView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 32,412 shares on 12/8/2022Ownership: 0.164%Christine A PellizzariBought 5,000 shares on 11/17/2022Total: $4,050.00 ($0.81/share)Alphabet Inc.Bought 3,207,260 shares on 11/16/2022Ownership: 2.749%Bank of New York Mellon CorpBought 32,412 shares on 11/15/2022Ownership: 0.164%Two Sigma Investments LPSold 46,220 shares on 11/15/2022Ownership: 0.054%View All Insider TransactionsView All Institutional Transactions SNCE Stock - Frequently Asked Questions Should I buy or sell Science 37 stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Science 37 in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SNCE shares. View SNCE analyst ratings or view top-rated stocks. What is Science 37's stock price forecast for 2023? 5 analysts have issued 12-month price objectives for Science 37's stock. Their SNCE share price forecasts range from $2.00 to $7.00. On average, they predict the company's stock price to reach $3.75 in the next twelve months. This suggests a possible upside of 756.4% from the stock's current price. View analysts price targets for SNCE or view top-rated stocks among Wall Street analysts. How have SNCE shares performed in 2023? Science 37's stock was trading at $0.4152 at the beginning of 2023. Since then, SNCE shares have increased by 5.5% and is now trading at $0.4379. View the best growth stocks for 2023 here. Are investors shorting Science 37? Science 37 saw a drop in short interest in the month of January. As of January 15th, there was short interest totaling 1,060,000 shares, a drop of 24.3% from the December 31st total of 1,400,000 shares. Based on an average daily trading volume, of 361,400 shares, the short-interest ratio is currently 2.9 days. Currently, 1.4% of the company's shares are short sold. View Science 37's Short Interest. When is Science 37's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023. View our SNCE earnings forecast. How were Science 37's earnings last quarter? Science 37 Holdings, Inc. (NASDAQ:SNCE) posted its quarterly earnings results on Thursday, November, 10th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.04. The firm earned $16.25 million during the quarter, compared to analysts' expectations of $20.60 million. Science 37 had a negative net margin of 66.46% and a negative trailing twelve-month return on equity of 72.32%. What guidance has Science 37 issued on next quarter's earnings? Science 37 issued an update on its FY 2022 earnings guidance on Saturday, December, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $68.20 million-$69.20 million, compared to the consensus revenue estimate of $80.68 million. What is Science 37's stock symbol? Science 37 trades on the NASDAQ under the ticker symbol "SNCE." How do I buy shares of Science 37? Shares of SNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Science 37's stock price today? One share of SNCE stock can currently be purchased for approximately $0.44. How much money does Science 37 make? Science 37 (NASDAQ:SNCE) has a market capitalization of $51.09 million and generates $59.60 million in revenue each year. The company earns $-94,330,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. How many employees does Science 37 have? The company employs 601 workers across the globe. How can I contact Science 37? Science 37's mailing address is 250 W 55TH ST. #3401, NEW YORK NY, 10019. The official website for the company is www.lifesciacquisition.com. The company can be reached via phone at 984-377-3737 or via email at investment@lifesciacquisition.com. This page (NASDAQ:SNCE) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.